Free Trial

RedHill Biopharma (RDHL) Stock Price, News & Analysis

+0.01 (+2.56%)
(As of 07/15/2024 ET)
Today's Range
50-Day Range
52-Week Range
230,202 shs
Average Volume
756,070 shs
Market Capitalization
$11.90 million
P/E Ratio
Dividend Yield
Price Target
RDHL stock logo

About RedHill Biopharma Stock (NASDAQ:RDHL)

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

RDHL Stock Price History

RDHL Stock News Headlines

The attacks will come for me after releasing this…
In my new exposé, I pull back the curtain on what’s really going on in America, what’s coming next, and what you must do to protect your assets before it’s too late.
The attacks will come for me after releasing this…
In my new exposé, I pull back the curtain on what’s really going on in America, what’s coming next, and what you must do to protect your assets before it’s too late.
RedHill Biopharma Ltd. (2RH0.F)
RedHill Biopharma Receives New Patent For H. Pylori Treatment Talicia
See More Headlines
Receive RDHL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RedHill Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded


Pretax Margin


Sales & Book Value

Annual Sales
$6.53 million
Cash Flow
$1.32 per share
Book Value
$0.11 per share


Free Float
Market Cap
$11.74 million
No Data
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Dror Ben-Asher (Age 58)
    Co-Founder, Chairman & CEO
    Comp: $594.61k
  • Mr. Razi Ingber (Age 40)
    Chief Financial Officer
    Comp: $339.82k
  • Mr. Gilead Raday MPhil (Age 49)
    MSc, Chief Operating Officer
    Comp: $365.56k
  • Mr. Adi Frish (Age 54)
    Chief Corporate & Business Development Officer
    Comp: $339.3k
  • Mr. Rick D. Scruggs (Age 64)
    Chief Commercial Officer, President of RedHill Biopharma Inc. & Director
    Comp: $469.8k
  • Ms. Alexandra Okmian
    Senior Business Development & Investor Relations Manager
  • Dr. Reza Fathi Ph.D. (Age 69)
    Senior Vice President of Research & Development
    Comp: $299.29k
  • Mr. Guy Goldberg J.D. (Age 48)
    Chief Business Officer
    Comp: $338.13k
  • Dr. June S. Almenoff FACP (Age 67)
    M.D., Ph.D., Chief Medical Officer
  • Ms. Patricia Anderson B.Sc. RAC
    Senior Vice President of Regulatory Affairs

RDHL Stock Analysis - Frequently Asked Questions

How have RDHL shares performed this year?

RedHill Biopharma's stock was trading at $1.46 at the beginning of 2024. Since then, RDHL shares have decreased by 72.6% and is now trading at $0.4007.
View the best growth stocks for 2024 here

How were RedHill Biopharma's earnings last quarter?

RedHill Biopharma Ltd. (NASDAQ:RDHL) issued its quarterly earnings results on Tuesday, November, 30th. The biotechnology company reported ($20.00) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($19.20) by $0.80. The biotechnology company earned $21.61 million during the quarter, compared to the consensus estimate of $23.41 million.

When did RedHill Biopharma's stock split?

RedHill Biopharma's stock reverse split on the morning of Thursday, March 23rd 2023. The 1-40 reverse split was announced on Thursday, March 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How do I buy shares of RedHill Biopharma?

Shares of RDHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of RedHill Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that RedHill Biopharma investors own include Agenus (AGEN), Sorrento Therapeutics (SRNE), Sangamo Therapeutics (SGMO), Verastem (VSTM), Amarin (AMRN), Aralez Pharmaceuticals (ARLZ) and Inovio Pharmaceuticals (INO).

This page (NASDAQ:RDHL) was last updated on 7/15/2024 by Staff

From Our Partners